Literature DB >> 12894529

In vitro and in vivo expression of somatostatin receptors in intermediate and malignant soft tissue tumors.

Tullio Florio1, Liliana Montella, Alessandro Corsaro, Annarosaria De Chiara, Gaetano Apice, Flavio Fazioli, Secondo Lastoria, Gennaro Schettini, Giovannella Palmieri.   

Abstract

BACKGROUND: Previous studies showed that the subtype 2 of somatostatin receptors (sstr2) is generally expressed by soft tissue sarcomas.
MATERIALS AND METHODS: Using reverse transcription-polymerase chain reaction (RT-PCR), the present study evaluated the expression of sstr mRNA in 31 human intermediate and malignant soft tissue tumors. In 8 patients somatostatin receptor scintigraphy was performed to detect soft tissue tumor sites and visualize in vivo sstr expression.
RESULTS: Somatostatin receptors were identified in 84% of the tumors analyzed by RT-PCR analysis. sstr1 and sstr2 were the receptors most frequently detected. Somatostatin receptor scintigraphy was able to identify primary and/or metastatic sites in 7 out of 8 patients, with an overall sensitivity per site of 87%. Concordant results were found between in vitro and in vivo techniques.
CONCLUSION: The wide expression of sstrs in soft tissue tumors suggest a relevant role for these receptors in diagnosis and may have therapeutic applications.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12894529

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

Review 1.  Somatostatin receptors and their interest in diagnostic pathology.

Authors:  Marco Volante; Francesca Bozzalla-Cassione; Mauro Papotti
Journal:  Endocr Pathol       Date:  2004       Impact factor: 3.943

2.  Imaging and therapy of hSSTR2-transfected tumors using radiolabeled somatostatin analogs.

Authors:  Zhe Wang; Wenhui Ma; Jing Wang; Jinglan Deng; Menghui Yuan; Mingxuan Zhao; Lintao Jia; Weidong Yang; Rui Zhang; Weiwei Qin; Dake Chu; Guoquan Li
Journal:  Tumour Biol       Date:  2013-04-19

3.  The role of somatostatin receptor scintigraphy on the diagnosis of desmoid tumors.

Authors:  Joerg Friesenbichler; Anja Molcan; Reingard Aigner; Patrick Sadoghi; Bernadette Liegl-Atzwanger; Werner Maurer-Ertl; Christian Weger; Andreas Leithner
Journal:  ISRN Oncol       Date:  2012-05-31

4.  A Patient With Metastatic Sarcoma was Successfully Treated With Radiolabeled Somatostatin Analogs.

Authors:  Aurora Crespo-Jara; Ramón González Manzano; Maribel Lopera Sierra; María Carmen Redal Peña; Antonio Brugarolas Masllorens
Journal:  Clin Nucl Med       Date:  2016-09       Impact factor: 7.794

Review 5.  Developments in the management of advanced soft-tissue sarcoma - olaratumab in context.

Authors:  Gianluca Moroncini; Elena Maccaroni; Ilaria Fiordoliva; Chiara Pellei; Armando Gabrielli; Rossana Berardi
Journal:  Onco Targets Ther       Date:  2018-02-16       Impact factor: 4.147

6.  Peptide receptor targeting in cancer: the somatostatin paradigm.

Authors:  Federica Barbieri; Adriana Bajetto; Alessandra Pattarozzi; Monica Gatti; Roberto Würth; Stefano Thellung; Alessandro Corsaro; Valentina Villa; Mario Nizzari; Tullio Florio
Journal:  Int J Pept       Date:  2013-02-07

7.  PET and PET/CT with 68gallium-labeled somatostatin analogues in Non GEP-NETs Tumors.

Authors:  Martina Sollini; Paola Anna Erba; Alessandro Fraternali; Massimiliano Casali; Maria Liberata Di Paolo; Armando Froio; Andrea Frasoldati; Annibale Versari
Journal:  ScientificWorldJournal       Date:  2014-02-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.